Overview
Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Completed
Trial end date:
2018-02-19
2018-02-19
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study evaluated the effect of secukinumab compared to placebo on aortic vascular inflammation in adult patients who have moderate to severe plaque psoriasis that is poorly controlled by current psoriasis treatments.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Novartis Pharmaceuticals
Criteria
Inclusion Criteria:- Males and females at least 18 years of age with moderate to severe plaque psoriasis
Exclusion Criteria:
- Forms of psoriasis other than chronic plaque psoriasis
- Previous exposure to IL-17A or IL-17 receptor targeting agents.
- Other active or ongoing disease that may interfere with evaluation of psoriasis or
places the patient at unacceptable risk
- Other protocol-defined inclusion/exclusion criteria may apply